BRCA1 and breast carcinoma: Walker et al. [15] used a pooled-RNA strategy to assess 27 LCLs derived from affected women in high-risk breast cancer families (9 BRCA1, 9 BRCA2 pathogenic variant carriers and 9 BRCAx) and 9 LCLs from healthy individuals, before and after treatment with mitomycin C. This study identified 36 genes which overlapped three different analyses that compared samples based on: (1) BRCA variant status, (2) mitomycin C treatment status and (3) disease status.